initial public offerings (IPOs) trading on American exchanges

Wednesday, February 3, 2016

BeiGene (BGNE) began trading on the Nasdaq on 3 Feb 2016

  • BeiGene, a Chinese developer of drugs that target a body’s immune system to fight cancer. With a team of more than 215 scientists and other staff members, it is creating a pipeline of oral drugs and antibodies to treat cancer.
  • There were 84 biotech companies that went public in the United States in 2014, the largest number on record, while last year 50 such companies conducted IPOs, according to Dealogic.

BeiGene (NASDAQ: BGNE) opened for trading at $28.97 after pricing of its initial public offering of 6,600,000 American Depositary Shares (ADS), each representing 13 of its ordinary shares, par value $0.0001 per share, at an initial public offering price of $24.00 per ADS.

Goldman, Sachs & Co., Morgan Stanley and Cowen and Company are acting as joint book-running managers. Baird is acting as co-manager of the offering.

BeiGene is a global, clinical-stage, research-based biotechnology company focused on targeted and immuno-oncological therapeutics. With a team of 215+ scientists and staff, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions aimed to have both a meaningful and a lasting impact on cancer patients.

No comments:

Post a Comment